Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QGEN | US
-2.00
-5.00%
Healthcare
Diagnostics & Research
30/06/2024
23/04/2026
37.97
38.90
38.94
37.40
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables such as nucleic stabilization and purification kits for primary sample materials manual and automated processing for genotyping gene expression and viral and bacterial analysis as well as silica membranes and magnetic bead technologies; secondary sample technology consumables including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV as well as assays for analysis of genomic variants such as mutations insertions deletions and fusions; and sample to insight instruments including one-step molecular analysis of hard-to-diagnose syndromes and integrated PCR testing. In addition it offers PCR consumables such as quantitative PCR reverse transcription and combinations kits for analysis of gene expression genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables including STR assays for human ID and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further the company provides predefined and custom NGS gene panels library prep kits and components and whole genome amplification; QIAGEN consumables and instruments as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics academia pharmaceutical and applied testing customers. The company was founded in 1986 and is headquartered in Venlo the Netherlands.
View LessGood Dividend Yield (2% <= Dividend Yield <= 8%)
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.6%1 month
29.2%3 months
26.7%6 months
36.1%122.86
18.66
2.81
0.41
0.25
28.43
5.19
1.17
364.74M
8.44B
8.44B
2.94
-32.31
-5.60
0.30
2.07
2.60
2.36
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.93
Range1M
4.93
Range3M
18.79
Rel. volume
1.56
Price X volume
71.99M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ICON Public Limited Company | ICLR | Diagnostics & Research | 106.34 | 8.81B | -7.87% | 34.54 | 37.38% |
| Charles River Laboratories International Inc | CRL | Diagnostics & Research | 167.74 | 8.66B | -9.23% | 23.63 | 76.32% |
| Bio-Rad Laboratories Inc | BIO | Diagnostics & Research | 281.42 | 7.80B | -6.44% | n/a | 20.54% |
| Lantheus Holdings Inc | LNTH | Diagnostics & Research | 82.82 | 5.75B | -0.07% | 19.19 | 60.42% |
| Bruker Corporation | BRKR | Diagnostics & Research | 36.22 | 5.48B | -8.70% | 26.13 | 126.86% |
| Sotera Health Company | SHC | Diagnostics & Research | 15.33 | 4.34B | -1.92% | 114.29 | 555.18% |
| Celcuity Inc | CELC | Diagnostics & Research | 113.56 | 4.21B | -7.24% | n/a | 54.62% |
| RadNet Inc | RDNT | Diagnostics & Research | 56.44 | 4.17B | -2.40% | 378.67 | 195.04% |
| Senseonics Holdings Inc | SENS | Diagnostics & Research | 7 | 3.75B | n/a | 154.97% | |
| Twist Bioscience Corporation | TWST | Diagnostics & Research | 58.85 | 3.45B | -6.88% | n/a | 17.75% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dolby Laboratories Inc | DLB | Media - Diversified | 62.96 | 6.00B | -3.03% | 34.32 | 0.00% |
| FBIN | FBIN | Building Products & Equipment | 41.4 | 5.14B | 2.15% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 78.81 | 4.17B | 1.04% | 23.44 | 27.88% |
| Cinemark Holdings Inc | CNK | Media - Diversified | 28.6 | 3.50B | 0.25% | 27.93 | 934.91% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 26.99 | 3.36B | -6.90% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 59.41 | 3.31B | 1.50% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.38 | 3.08B | 1.96% | 7.33 | 218.58% |
| LCI Industries | LCII | Recreational Vehicles | 120.55 | 3.07B | 0.73% | 25.82 | 77.66% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.37 | 2.76B | 0.99% | n/a | -571.93% |
| IMAX Corporation | IMAX | Media - Diversified | 36.61 | 1.93B | 1.08% | 54.26 | 110.44% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 28.43 | 12.67 | Expensive |
| Ent. to Revenue | 5.19 | 44.00 | Cheaper |
| PE Ratio | 122.86 | 40.09 | Expensive |
| Price to Book | 2.81 | 77.50 | Cheaper |
| Dividend Yield | 2.94 | 1.18 | Leader |
| Std. Deviation (3M) | 26.68 | 59.59 | Lower Risk |
| Debt to Equity | 0.41 | -14.36 | Expensive |
| Debt to Assets | 0.25 | 0.34 | Cheaper |
| Market Cap | 8.44B | 13.71B | Emerging |